Glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) potently amplify insulin secretion and influence satiety to reduce food intake1,2,3. Stabilized GLP1R agonists were approved for the treatment of type 2 diabetes in 2008 (ref. 4) and at higher doses for overweight and obesity in 2017 and 2018 (ref. 5). Less attention has been paid to the GIP axis, as multiple …
Read More »Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
